China Biologic Products Holdings, Inc. (CBPO) At $81.00 Forms Bottom; Shorts at Urogen Pharma LTD. – Ordinary Shares (URGN) Lowered By 10.08%

Urogen Pharma LTD. – Ordinary Shares (NASDAQ:URGN) had a decrease of 10.08% in short interest. URGN’s SI was 106,100 shares in March as released by FINRA. Its down 10.08% from 118,000 shares previously. With 222,900 avg volume, 1 days are for Urogen Pharma LTD. – Ordinary Shares (NASDAQ:URGN)’s short sellers to cover URGN’s short positions. The SI to Urogen Pharma LTD. – Ordinary Shares’s float is 1.25%. The stock decreased 0.38% or $0.19 during the last trading session, reaching $49.69. About 130,578 shares traded or 0.46% up from the average. Urogen Pharma Ltd. (NASDAQ:URGN) has 0.00% since March 31, 2017 and is . It has underperformed by 11.55% the S&P500.

China Biologic Products Holdings, Inc. (CBPO) formed multiple bottom with $74.52 target or 8.00% below today’s $81.00 share price. China Biologic Products Holdings, Inc. (CBPO) has $2.68B valuation. The stock decreased 0.01% or $0.01 during the last trading session, reaching $81. About 129,557 shares traded. China Biologic Products Holdings, Inc. (NASDAQ:CBPO) has declined 18.54% since March 31, 2017 and is downtrending. It has underperformed by 30.09% the S&P500.

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing therapies for urological pathologies. The company has market cap of $756.02 million. The Company’s lead product candidates, MitoGel and VesiGel are formulations of the chemotherapy drug Mitomycin C, a generic drug which is currently used off-label for urothelial cancer treatment only in a water formulation as an adjuvant, or supplemental post-surgery, therapy. It currently has negative earnings. The firm is developing its product candidates as chemoablation agents, which are designed to remove tumors by non-surgical means, to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, and low-grade bladder cancer.

Among 2 analysts covering China Biologic Products (NASDAQ:CBPO), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. China Biologic Products has $162 highest and $97.0 lowest target. $101’s average target is 24.69% above currents $81 stock price. China Biologic Products had 8 analyst reports since September 4, 2015 according to SRatingsIntel. As per Friday, September 4, the company rating was maintained by Jefferies. The stock of China Biologic Products Holdings, Inc. (NASDAQ:CBPO) earned “Buy” rating by Jefferies on Tuesday, September 12. As per Friday, October 13, the company rating was maintained by Jefferies. Jefferies maintained the stock with “Buy” rating in Thursday, August 3 report. The stock of China Biologic Products Holdings, Inc. (NASDAQ:CBPO) earned “Buy” rating by Jefferies on Monday, June 12. The stock of China Biologic Products Holdings, Inc. (NASDAQ:CBPO) earned “Buy” rating by Jefferies on Thursday, March 15.

Analysts await China Biologic Products Holdings, Inc. (NASDAQ:CBPO) to report earnings on May, 2. They expect $1.28 EPS, down 3.03% or $0.04 from last year’s $1.32 per share. CBPO’s profit will be $42.41 million for 15.82 P/E if the $1.28 EPS becomes a reality. After $0.90 actual EPS reported by China Biologic Products Holdings, Inc. for the previous quarter, Wall Street now forecasts 42.22% EPS growth.

Urogen Pharma Ltd. (NASDAQ:URGN) Ratings Chart